This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

milvexian
Medical Information

Milvexian - Comparison to Asundexian

Last Updated: 11/17/2026

SUMMARY

  • No prospective, randomized, head-to-head trials comparing the efficacy and safety of milvexian and asundexian have been conducted. Therefore, based on the lack of clinical evidence, no direct comparative conclusions can be drawn.

BRISTOL MYERS SQUIBB AND JOHNSON & JOHNSON COLLABORATION

Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.

To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.

To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.

CLINICAL STUDIES

No prospective, randomized, head-to-head trials comparing the efficacy and safety of milvexian and asundexian have been conducted. Therefore, based on the lack of clinical evidence, no direct comparative conclusions can be drawn.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 15 September 2026.

Would you like to clear and leave your conversation? Message history will be lost.